Seres Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an Amendment No. 14 to Schedule 13G, reporting a beneficial ownership of 3.1% in Seres Therapeutics Inc. common stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 5.7% Passive Stake in Seres Therapeutics Inc.
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a 5.7% beneficial ownership stake in Seres Therapeutics Inc. as of May 30, 2025.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 12.8% Stake in Seres Therapeutics
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming their beneficial ownership of 12.8% of Seres Therapeutics Inc.'s common stock as of December 31, 2024.